PolyMedix, Inc. (OTC BB: PYMX)

PolyMedix, Inc is a development-stage biotechnology company focusing on treating serious, life-threatening acute disorders with biomimetics – novel small molecule drugs which mimic the activity of proteins. These are designed with a proprietary computational technology. The Company is developing products in two therapeutic areas: infectious diseases, with novel antibiotic drugs which mimic the activity of the host defense proteins; and acute cardiovascular, with a new heparin antagonist. PolyMedix has two novel drugs in clinical development - PMX-30063, a novel small molecule defensin-mimetic antibiotic drug, and PMX-60056, a unique reversing agent for heparin and low molecular weight heparins.